#1 Clinical Trials Search in Europe

2-Isopropyl-3H-Naphtho(1,2-D)Imidazole-4,5-Dione

This article discusses the ongoing clinical trials investigating the use of KL1333, also known as 2-Isopropyl-3H-Naphtho(1,2-D)Imidazole-4,5-Dione, in adult patients with primary mitochondrial disease. The study aims to evaluate the drug’s effectiveness in managing fatigue symptoms, improving physical function, and assessing its impact on disease progression. This research is crucial for developing potential treatments for this rare genetic disorder affecting cellular energy production.

Table of Contents

What is KL1333?

KL1333, also known as 2-isopropyl-3h-naphtho(1,2-d)imidazole-4,5-dione, is a new medication being studied for the treatment of primary mitochondrial disease in adults[1]. It is currently undergoing clinical trials to evaluate its effectiveness and safety. KL1333 is taken as a tablet and is being developed by Abliva AB[1].

Primary Mitochondrial Disease: An Overview

Primary mitochondrial disease (PMD) is a group of genetic disorders that affect the mitochondria, which are tiny structures inside our cells that produce energy. When mitochondria don’t work properly, it can lead to various health problems affecting multiple body systems[1]. Some common symptoms of PMD include:

  • Fatigue (extreme tiredness)
  • Muscle weakness
  • Exercise intolerance (difficulty with physical activities)
  • Problems with balance and coordination
  • Vision and hearing issues
  • Neurological problems

How KL1333 Works

While the exact mechanism of action is not fully described in the provided information, KL1333 is believed to target the underlying issues in mitochondrial function. It aims to improve energy production in cells, which could potentially alleviate some of the symptoms associated with primary mitochondrial disease[1].

Potential Benefits of KL1333

The clinical trial is designed to evaluate several potential benefits of KL1333 for patients with primary mitochondrial disease[1]:

  • Reduction in fatigue and its impact on daily life
  • Improvement in lower extremity strength and endurance
  • Enhanced physical function and ability to perform daily activities
  • Possible slowing of disease progression
  • Potential improvement in blood sugar control for patients with diabetes

Clinical Trial Details

The clinical trial for KL1333 is designed to thoroughly evaluate its effectiveness and safety[1]. Here are some key details:

  • It is a randomized, double-blind, placebo-controlled study. This means that participants will be randomly assigned to receive either KL1333 or a placebo (a pill with no active ingredient), and neither the patients nor the researchers will know who is receiving which treatment until the study is completed.
  • The trial will last for 48 weeks (about 11 months).
  • Participants will take the medication orally (by mouth) as a tablet.
  • The maximum daily dose being tested is 100 mg.

Eligibility Criteria

To participate in the KL1333 clinical trial, patients must meet certain criteria[1]. Some key eligibility requirements include:

  • Being 18 years or older
  • Having a confirmed diagnosis of primary mitochondrial disease caused by specific genetic mutations
  • Experiencing chronic mitochondrial fatigue for at least 3 months
  • Having some level of muscle weakness or reduced exercise tolerance
  • Being able to perform certain physical tests, such as the 30-second sit-to-stand test

There are also several conditions that would exclude a person from participating, such as certain other medical conditions or use of specific medications. It’s important to discuss all aspects of eligibility with a healthcare provider or the study team.

What to Expect During the Trial

Participants in the KL1333 trial can expect the following[1]:

  • Regular check-ups and medical evaluations
  • Completion of questionnaires about fatigue, physical function, and quality of life
  • Physical tests to assess muscle strength and endurance
  • Blood tests to monitor overall health and, for diabetic patients, blood sugar control
  • Assessments of disease progression using specialized scales

Safety Considerations

As with any clinical trial, there are important safety considerations for participants[1]:

  • The trial excludes people with certain medical conditions to minimize risks.
  • Participants must agree to use effective contraception methods during the study and for a period after, as the effects of KL1333 on pregnancy are unknown.
  • Regular medical check-ups and laboratory tests will be conducted to monitor for any potential side effects.
  • Participants should inform the study team about any changes in their health or medications during the trial.

It’s important to note that while KL1333 shows promise, it is still an experimental treatment. The purpose of this clinical trial is to determine its effectiveness and safety. If you’re considering participating in this or any clinical trial, it’s crucial to discuss it thoroughly with your healthcare provider and the study team to understand all potential risks and benefits.

Aspect Details
Study Drug KL1333 (2-Isopropyl-3H-Naphtho(1,2-D)Imidazole-4,5-Dione)
Condition Primary Mitochondrial Disease in Adults
Study Design Randomized, double-blind, placebo-controlled, flexible-dose, adaptive study
Duration 48 weeks
Primary Objectives Evaluate efficacy on fatigue symptoms and impacts on daily living; Assess functional lower extremity strength and endurance
Key Inclusion Criteria Age 18+; Confirmed PMD diagnosis; Chronic mitochondrial fatigue; Presence of mitochondrial myopathy
Key Exclusion Criteria Predominant neurodegenerative phenotypes; Use of idebenone within 14 days prior to first dose; Significant cardiovascular disease
Primary Endpoints PROMIS Fatigue PMD short form; 30 Second Sit-to-Stand Test (30s STS)
Secondary Endpoints Neuro-QOL Lower Extremity Function; Patient and Clinician Global Impression scales; NMDAS Subscales I-III; HbA1c in patients with diabetes

FAQ

  • What is KL1333 and what is it being studied for? KL1333 is a drug being studied for the treatment of primary mitochondrial disease in adults. It's being tested to see if it can help with fatigue symptoms, improve muscle strength and endurance, and slow down disease progression.
  • How long does the clinical trial last? The clinical trial lasts for 48 weeks, during which participants receive either KL1333 or a placebo.
  • What are the main goals of the study? The main goals are to evaluate KL1333's effectiveness in reducing fatigue, improving lower extremity strength and endurance, and assessing its impact on daily living activities for patients with primary mitochondrial disease.
  • Who can participate in this clinical trial? Adults aged 18 or older with a confirmed diagnosis of primary mitochondrial disease, who experience chronic fatigue and have some level of muscle weakness, may be eligible to participate. There are specific inclusion and exclusion criteria that determine eligibility.
  • How is the effectiveness of KL1333 being measured? The effectiveness is being measured through various tests and questionnaires, including the PROMIS Fatigue PMD short form for fatigue assessment, the 30 Second Sit-to-Stand Test for physical function, and the Newcastle Mitochondrial Disease Adult Scale for disease progression.

Ongoing Clinical Trials on 2-Isopropyl-3H-Naphtho(1,2-D)Imidazole-4,5-Dione

  • Long-Term Safety and Efficacy of KL1333 in Adults with Primary Mitochondrial Disease

    Not yet recruiting

    2 1 1
    Investigated drugs:
    Belgium Czechia Denmark France Germany Italy +1

Glossary

  • Primary Mitochondrial Disease (PMD): A group of genetic disorders that affect the mitochondria, which are structures in cells that produce energy. These diseases can cause a wide range of symptoms and affect multiple organ systems.
  • KL1333: The study drug, also known as 2-Isopropyl-3H-Naphtho(1,2-D)Imidazole-4,5-Dione, being investigated for the treatment of primary mitochondrial disease.
  • Fatigue: A feeling of tiredness or lack of energy that is a common symptom in mitochondrial diseases.
  • Myopathy: Muscle weakness or disease, which is often present in patients with mitochondrial disorders.
  • PROMIS Fatigue PMD Short Form: A questionnaire used to assess fatigue levels in patients with primary mitochondrial disease.
  • 30 Second Sit-to-Stand Test (30s STS): A physical test that measures lower body strength and endurance by counting how many times a person can stand up from a seated position in 30 seconds.
  • Newcastle Mitochondrial Disease Adult Scale (NMDAS): A clinical assessment tool used to evaluate the severity and progression of mitochondrial disease in adults.
  • Placebo: An inactive substance that looks like the study drug but contains no active medication, used as a control in clinical trials.
  • Double-blind study: A type of clinical trial where neither the participants nor the researchers know who is receiving the actual drug and who is receiving the placebo.
  • Heteroplasmy: The presence of both normal and mutated mitochondrial DNA within a single cell, which can affect the severity of mitochondrial disease.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-kl1333-for-adults-with-primary-mitochondrial-disease/